AnaptysBio Shares Rise 11% After Jemperli Plus Chemotherapy Approved in U.S.
By Chris Wack
AnaptysBio shares were 11% higher after GSK received U.S. Food and Drug Administration approval for a treatment indication using a drug it licenses from AnaptysBio.
The FDA on Monday approved Jemperli plus carboplatin and paclitaxel, or chemotherapy, for the treatment of adult patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer.
AnaptysBio shares hit their 52-week low of $16.66 on Thursday, and are down 9% in the past 12 months.
The supplemental Biologics License Application supporting this new indication received Priority Review and was approved ahead of the Sept. 23 Prescription Drug User Fee Act action date.
The dual-primary endpoints in Part 1 of the trial are investigator-assessed progression-free survival and overall survival.
Jemperli was discovered by AnaptysBio and licensed to Tesaro, now a part of the GSK group of companies, under a collaboration and exclusive license agreement signed in March 2014. GSK is responsible for the ongoing development and commercialization of Jemperli. AnaptysBio is entitled to receive milestones and tiered royalties of 8% for net sales of Jemperli below $1 billion and 12% up to 25% of sales above $1 billion.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 31, 2023 14:12 ET (18:12 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025